Market Research Logo

Allergic Asthma - Pipeline Review, H2 2015

Allergic Asthma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Allergic Asthma - Pipeline Review, H2 2015’, provides an overview of the Allergic Asthma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Allergic Asthma Overview
Therapeutics Development
Pipeline Products for Allergic Asthma - Overview
Pipeline Products for Allergic Asthma - Comparative Analysis
Allergic Asthma - Therapeutics under Development by Companies
Allergic Asthma - Therapeutics under Investigation by Universities/Institutes
Allergic Asthma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Allergic Asthma - Products under Development by Companies
Allergic Asthma - Products under Investigation by Universities/Institutes
Allergic Asthma - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Array BioPharma Inc.
Aslan Pharmaceuticals Pte. Ltd.
BioTech Tools s.a.
CSL Limited
Fountain Biopharma Inc.
GlaxoSmithKline Plc
Infinity Pharmaceuticals, Inc.
Kineta, Inc.
Mabtech AB
Marinomed Biotechnologie GmbH
NeoPharm Co., Ltd.
Novartis AG
Nuvo Research Inc.
Oxagen Limited
Panacea Biotec Limited
Peptinnovate Limited
Pharmaxis Limited
Portola Pharmaceuticals, Inc.
Protectimmun GmbH
Pulmatrix, Inc.
Stallergenes S.A.
sterna biologicals Gmbh & Co KG
Swecure AB
The International Biotechnology Center (IBC) Generium
Verona Pharma Plc
Allergic Asthma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(fluticasone propionate + salmeterol xinafoate) - Drug Profile
AcTMP-1 - Drug Profile
Arabinogalactan - Drug Profile
ARRY-502 - Drug Profile
ASLAN-004 - Drug Profile
ASM-8 - Drug Profile
beta-escin - Drug Profile
CSL-311 - Drug Profile
dalazatide - Drug Profile
Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile
duvelisib - Drug Profile
FB-825 - Drug Profile
fevipiprant - Drug Profile
GNR-044 - Drug Profile
GSK-2245035 - Drug Profile
hdm-ASIT - Drug Profile
Lactococcus lactis G121 - Drug Profile
ligelizumab - Drug Profile
MK-8237 - Drug Profile
OC-000459 - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
pemirolast potassium - Drug Profile
pentosan polysulfate sodium - Drug Profile
PIN-201601 - Drug Profile
PRT-2607 - Drug Profile
RPL-554 - Drug Profile
SB-010 - Drug Profile
SG-100 - Drug Profile
Small Molecule for Allergic Asthma - Drug Profile
Small Molecules for Allergic Asthma - Drug Profile
Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile
STG-320 - Drug Profile
SWE-01 - Drug Profile
Timothy Grass Pollen Allergen Extract - Drug Profile
Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile
WF-10 liposomal - Drug Profile
Allergic Asthma - Recent Pipeline Updates
Allergic Asthma - Dormant Projects
Allergic Asthma - Discontinued Products
Allergic Asthma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Allergic Asthma, H2 2015
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Allergic Asthma - Pipeline by ALK-Abello A/S, H2 2015
Allergic Asthma - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015
Allergic Asthma - Pipeline by Array BioPharma Inc., H2 2015
Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
Allergic Asthma - Pipeline by BioTech Tools s.a., H2 2015
Allergic Asthma - Pipeline by CSL Limited, H2 2015
Allergic Asthma - Pipeline by Fountain Biopharma Inc., H2 2015
Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H2 2015
Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Allergic Asthma - Pipeline by Kineta, Inc., H2 2015
Allergic Asthma - Pipeline by Mabtech AB, H2 2015
Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2015
Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H2 2015
Allergic Asthma - Pipeline by Novartis AG, H2 2015
Allergic Asthma - Pipeline by Nuvo Research Inc., H2 2015
Allergic Asthma - Pipeline by Oxagen Limited, H2 2015
Allergic Asthma - Pipeline by Panacea Biotec Limited, H2 2015
Allergic Asthma - Pipeline by Peptinnovate Limited, H2 2015
Allergic Asthma - Pipeline by Pharmaxis Limited, H2 2015
Allergic Asthma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
Allergic Asthma - Pipeline by Protectimmun GmbH, H2 2015
Allergic Asthma - Pipeline by Pulmatrix, Inc., H2 2015
Allergic Asthma - Pipeline by Stallergenes S.A., H2 2015
Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015
Allergic Asthma - Pipeline by Swecure AB, H2 2015
Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
Allergic Asthma - Pipeline by Verona Pharma Plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Allergic Asthma Therapeutics - Recent Pipeline Updates, H2 2015
Allergic Asthma - Dormant Projects, H2 2015
Allergic Asthma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Allergic Asthma, H2 2015
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report